Lupin has received final approval for its Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA) to market generic version of Benicar tablets, 5 mg, 20 mg and 40 mg. Benicar tablets had US sales of $1,036 million, as per IMS MAT December 2016.
Lupin's Olmesartan Medoxomil tablets, 5 mg, 20 mg and 40 mg are the AB rated generic equivalent of Daiichi Sankyo Inc.'s Benicar tablets. It is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: